Reimbursement Review Reports


( Last Updated : May 25, 2022)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Baraclude Entecavir Hepatitis B (chronic) List with clinical criteria and/or conditions Complete
Basaglar Insulin glargine Diabetes mellitus, type 1; diabetes mellitus, type 2 List with clinical criteria and/or conditions Complete
Benlysta Belimumab Systemic lupus erythematosus Do not list Complete
Benlysta Belimumab systemic lupus erythematosus Do not reimburse Complete
Beovu brolucizumab Macular degeneration, age-related Reimburse with clinical criteria and/or conditions Complete
Bijuva estradiol and progesterone Vasomotor symptoms associated with menopause Reimburse with clinical criteria and/or conditions Complete
Biktarvy bictegravir/emtricitabine/tenofovir alafenamide HIV-1 infection Reimburse with clinical criteria and/or conditions Complete
Bimzelx bimekizumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Active
Botox onabotulinumtoxinA Migraine, chronic Reimburse with clinical criteria and/or conditions Complete
Botox OnabotulinumtoxinA Neurogenic detrusor overactivity List with clinical criteria and/or conditions Complete